Trials / Terminated
TerminatedNCT00651443
Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma
A Phase I, Open Label Study to Evaluate the Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the mechanism(s) of action of galiximab in subjects with previously untreated follicular NHL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Galiximab | Galiximab 500 mg/m2 IV once weekly times 4, followed by Galiximab 500 mg/m2 IV once monthly times 4 as an extended dosing regimen. |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2010-11-01
- Completion
- 2010-12-01
- First posted
- 2008-04-02
- Last updated
- 2011-01-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00651443. Inclusion in this directory is not an endorsement.